Skip to content
Company Analysis

Boston Scientific Corporation BSX

A comprehensive view of key metrics, scores, and financial health for Boston Scientific Corporation

Overview of Boston Scientific Corporation

BSX NYQ
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Large Cap
Boston Scientific Corporation (BSX), is a Large Cap company, in the Medical Devices industry, last closed at $42.97, about 46.4% overvalued vs fair value, -59.8% 1Y return, placing in the top 25% of its sector.
Metrics P/E 49.2× Rev Growth 19.9% ROE 12.6% Gross Margin 69.0%
USD 42.97
-0.51%
(Delayed)
• Vol 90d: 43.6%
52-Week Range
Market Cap
$66.87B
Enterprise Value
$76.45B
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Excellent
Health
Good
Efficiency
Fair
Valuation
Good
Growth
Good
Profitability
Excellent
Health
Good
Efficiency
Fair
Valuation
Good
Completeness: 82%
Confidence: 86%
Updated: Jul 5
Top Beats

Quick Facts

Website https://www.bostonscientific.c...
HQ Marlborough, MA
Employees 59,000
Fiscal year Dec 31

Next Events

Earnings Jul 29 Call: Jul 29

Fair Value Snapshot

Bear Base Bull
$20
$23
$26
Current: $42.97 -46% vs base

Engine Room Money Flow™

Large Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$20.1B
19.9%%
Gross Profit
$13.9B
20.6%%
Operating Income (GAAP)
$4.0B
32.3%%
EBITDA
$5.1B
32.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
69.0%
Excellent

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$230.0M
9.7% of Free Cash Flow

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Boston Scientific Corporation's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
77
/100
Strong
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Strong
85
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing BSX's balance between Growth (34.8%), Profitability (38.3%), and Safety (27.0%). Growth 35% Safety 27% Profitability 38%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

76th percentile vs peers
77
Key Signals
Rev Growth YoY 19.9% 77p EPS CAGR 3Y 63.1% 91p Revenue CAGR 3Y 16.5% 68p EPS Growth YoY 55.4% 66p TSR 79.5% 90p
Strengths
  • EPS CAGR 3Y in top 20% of peers (63.1%, 91th percentile)
  • FCF Margin in top 20% of peers (17.0%, 89th percentile)
  • Operating Margin in top 20% of peers (19.8%, 91th percentile)
  • ROIC in top 20% of peers (9.5%, 83th percentile)
Risks

No significant risks identified for this axis.

Profitability

84th percentile vs peers
84
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

59th percentile vs peers
60
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Boston Scientific Corporation.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$23.04
- - -
-46.4% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000